Major Cardiovascular Event Risk Reduction with Pitavastatin in People Living with HIV

A large randomized, controlled trial (REPRIEVE) conducted by Grinspoon and colleagues showed that in participants living with human immunodeficiency virus (HIV) who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin had a 35% lower risk of experiencing a major adverse cardiovascular event over a follow-up of approximately five years than those who received placebo.